Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 17/20 | 0.67 |
| ▸ | EDNRA | P25101 | 17/20 | 0.67 |
| ▸ | DHPS | P49366 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653603 | 0.89 | EDNRB (0.65) | EDNRBEDNRA | |
| SCHEMBL5764890 | 0.89 | EDNRB (0.54) | EDNRBEDNRA | |
| SCHEMBL6289572 | 0.87 | EDNRB (0.59) | EDNRBEDNRA | |
| SCHEMBL4068803 | 0.85 | DHPS (0.61) | EDNRBEDNRADHPS | |
| SCHEMBL6289571 | 0.83 | EDNRB (0.59) | EDNRBEDNRA | |
| SCHEMBL14380727 | 0.81 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL1383888 | 0.80 | EDNRB (0.74) | EDNRBEDNRA | |
| SCHEMBL7480398 | 0.80 | EDNRB (0.72) | EDNRBEDNRA | |
| SCHEMBL7479954 | 0.80 | EDNRB (0.72) | EDNRBEDNRA | |
| SCHEMBL7841637 | 0.79 | EDNRB (0.54) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309564-B1 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-14 | — | — | EP | claimed |
| US-6951856-B2 | Arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-10-04 | — | — | US | claimed |
| JP-2004504385-A | — | — | 2004-02-12 | — | — | JP | claimed |
| US-20030220359-A1 | Novel arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-11-27 | — | — | US | claimed |
| EP-1309564-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-05-14 | — | — | EP | claimed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | claimed |
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | disclosed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | BOLLI MARTIN | 2006-08-10 | — | — | US | disclosed |
| EP-1309564-B1 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-14 | — | — | EP | disclosed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | disclosed |
| US-20030220359-A1 | Novel arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1309564-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-05-14 | — | — | EP | disclosed |
| EP-0959072-B1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | disclosed |
| EP-0959072-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5739333-A | 4-SULFONAMIDO-6-ARYLOXY OR -AMINOALKYLENEOXY,-AMINO, OR -THIOPYRIMIDINES; ENDOLTHELIN ANTAGONISTS; HYPOTENSIVE AND ULCER AGENTS; ASTHMA; RAYNAUD DISEASE; CARDIOVASCULAR DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0743307-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1996-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220359-A1 | Novel arylethene-sulfonamides | EDNRA, ECE2, ECE1 | EDNRB 4/4885EDNRA 1/4885DHPS 424/4885 |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | EDNRA, EDNRB, ECE2 | EDNRB 2/4885EDNRA 1/4885DHPS 273/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885DHPS 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.